Most patients notice visible changes within 34 weeks
GIP (Glucose-dependent Insulinotropic Polypeptide): Another incretin hormone produced in the intestines Stimulates insulin secretion from the pancreas Enhances fat metabolism Affects how the body stores and uses energy May amplify the appetite-suppressing effects of GLP-1 The Combined Effect: When both GLP-1 and GIP pathways are activated together: Stronger insulin response: better blood sugar control Enhanced fat burning: greater weight loss More appetite suppression: reduced food intake Slower gastric emptying: prolonged fullness (and potential problems) Clinical Advantages of Tirzepatide Greater Weight Loss: Clinical trials showed tirzepatide produced: Average weight loss: 20-25% of body weight Compared to semaglutide: 15-20% Some patients lost 30%+ of their starting weight Faster Results: Many patients report: Quicker onset of appetite suppression More rapid weight loss in the first months Stronger fullness sensation after meals Superior Glucose Control: For diabetic patients: Greater A1C reductions than semaglutide More patients reaching target A1C goals Fewer patients needing additional diabetes medications Potential Disadvantages and Risks 1
Li DJ, Huang F, Lu WJ, Jiang GJ, Deng YP, Shen FM
Consumption of diets with low advanced glycation end products improves cardiometabolic parameters: meta-analysis of randomised controlled trials
However, eating slowly, choosing bland foods, and staying hydrated can reduce symptom severity by 4060%
However, it is always wise to follow the specific dosage instructions on the product label and consult with a healthcare professional if you have underlying concerns
.jpeg)
